Why Was Ensysce Biosciences Stock Up on Aug 6, 2026?

Ensysce Biosciences shares are trading sharply higher in pre-market trading today, extending an initial jump that followed this morning's announcement that the clinical-stage biotech had completed its acquisition of Cy Biopharma, a privately held developer of neuroplastogenic therapies for pain conditions, with an initial focus on Complex Regional Pain Syndrome (CRPS).

The acquisition came with financing attached: $17.1 million in cash financing and a $21.5 million Series C preferred stock private placement, with a potential further $38.6 million follow-on tranche tied to a clinical trial milestone — as much as $77.2 million in total, intended to fund Cy Biopharma's lead program, CY200, through 2028. Unlike most of today's stock movers, this is a corporate development and financing story rather than an earnings reaction; the market's response reflects how investors are pricing the newly combined pipeline and the capital secured to fund it. For the full breakdown, see our dated report on the acquisition and financing.